Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep...always take your profits. Up 150% would have been nice...good luck getting green.
"Accumulation" on very small volume. More volume in the last 2 days than the last month. All those accumulated shares could have been dumped yesterday for all we know.
Here's a funny story to blend in with all the drama on this board.
Saw EPIX on my ETrade scanner yesterday. Saw your post on IHUB. Pulled up the link and saw it was dated 11/4. Pulled a chart and thought, hey maybe this will work.
Bought 30K at .017. Watched it go up to .045 and I was $700+ in the green. Then I watched it start to fall. Checked IHUB and saw all the posters trying to save our lives. Thought it might go back up. Not with all the alerts to save our souls.
Anyway, I am in the hole some now, but the only one I can blame is myself because I wanted more profit. Greed got me again!
I'll see what the scanner pulls up tomorrow.
Well then you must have been watching the accumulation over the past several weeks and the sec document from a private company.
Someone has to balance out all the "positive spin" being slung around. I have been watching Epix for a long time and hate to see folks suckered in by blatantly false posts.
If you sold your shares, why are you so concerned with EPIX?
I stand corrected...but you were dead wrong about the merger.
IMO a PR will not come at all. Karyopharm is a long way from being ready to go public. They just received $20 million so they certainly don't need to raise any funds right now.
Wrong, I have not disappeared and currently hold shares of EPIX. Thank you very much...........
Absolutely not...some here believe Karyopharm may some day merge into the EPIX shell. They are basing that belief on the fact that Karyopharm's co-founder was also the founder of Predix (who merged with Epix in 2006). That's it...nothing more. Very tenuous at best.
I realize that you are entitled to your opinion, but you have zero facts to back that up. You're putting all your eggs in the common personnel basket. That's a big stretch.
Don't worry. You will make a profit... and sooner than you think.
Closed higher than Tuesdays close and had a higher low than yesterday. The sky didn't fall and it is still in an upward trend. I must admit that I can be a little optimistic since I got in at .015 and am close to getting back even. However, I have been in some ships that dropped to the bottom on a day after a big runnup. This one didn't, still trending higher!! I make make a profit yet.
Lot's of long time investors angered by current loss positions. Completely understandable. However, EPIX has transactions in the works (IMO) that will payoff really big for current investors. Patience is a virtue, but is tested especially during such volatility. Stay the course....
I am sorry to the investor that bought my shares in the .03 ranges. Yes it is sinful money, but I have to take it. I got hit hard last year with the worst FDA approval news ever (FDA approaval, but company could not dig out of debt).
Who ever pump EPIX with that bad news should either be hang or give an award. This is a rare pump that came from board members rather company. Once again I am sorry for enjoying your money (blood money in this bad economy).
Can't PM you, Thanks.
Then why was the price hike yesterday?
No, it has nothing at all to do with EPIX.
Can somebody please tell me does the $20 Million Series A Financing to Karyopharm Therapeutics Inc. have anything to do with EPIX?
Panic sellers gone. Nice tree shake. MM games.
Looks like a up tick from here...there was support at .012 yesterday at the end of the day....GL
EPIX nice accumulation @.011, setting up for another run.
Exactly. Shares held by stronger hands. Moving up.
Hope all the weak hands are gone!!!.....time to start moving again.......
Is there news? Whats the S/S
I hear that EPIX might merge with Google, and that the merged entity will then perform a hostile takeover of both Apple and Microsoft. All happening under the EPIX name, of course.
Sound foolish? Well, an employee at EPIX was seen looking something up on the internet with google search engine. So there's a connection.
Do you have a single shred of evidence that could state the possibility that Google may not merge into EPIX?
I just made a factless, unsupported speculation. But all reverse merger plays are speculation, right? So this should shoot to hundereds of dollars because that's where google is!!
(end sarcasm)
Really, the burden of proof is on you to show evidence that SUPPORTS the proposition of a merger between karyopham and EPIX. The burden of proof is not on someone to DISPROVE something that has no basis in fact and is only speculation.
All IMO, of course.
OMG WHATS THE L2 LOOK LIKE DOWN SHE GOES
The biggest gains are made when you buy before the announcement. Most times when an announcement is made, the price appreciation is already baked into the price.
A PR from the company will not come out until they have a signed agreement. So until then, investors are posturing and taking positions anticipating a possible business combination.
I agree...it is possible. But I have seen nothing to indicate it's going to happen anytime soon. The run yesterday was based on the idea that it was a done deal. That premise was totally false and the pps will adjust accordingly IMO.
Just curious on your opinion. New support looks like .01. I am thinking that is the smartest entry point.
Any thoughts?
Thanks.
Again please don't try to make it look bad..The way it was represented yesterday was bad. But we are talking of the possibility to get merged with EPIX.
Give me your impression on why this may not happen?
Do you have a single evidence that could state the possibility that Karyopharm may not merge into EPIX?
We are all talking about speculation here. ALL REVERSE MERGE PLAYS ARE SPECULATIVE UNTIL ITS A DONE DEAL.
No one that matters...this was run up on misunderstood PR. Now people scrambling to make connections that aren't there.
EPIX will test 4's. Solid base formed. IMO of course.
Smart money bought in yesterday. Volume precedes price
Alerts went yesterday. Huge retracement triggered buy signal. The catalyst for a stampede to establish positions.
lol "huge move expected" by WHOM??
$120.00...lol thats it.
Karyopharm Therapeutics Inc.
D Filing
Filed 2010-11-05
13. Offering and Sales Amounts
Total Offering Amount $ 20750000
USD Indefinite
Total Amount Sold $ 700000
USD
Total Remaining to be Sold $ 20050000
USD Indefinite
Clarification of Response (if Necessary)
In addition to the amount sold above, the Issuer issued $10,050,000 of securities under Regulation S; as a result $10,000,000 remains to be sold.
http://secwatch.com/filings/view.jsp?formid=7420108
hmmmm you got something there http://secwatch.com/filings/view.jsp?formid=7420108
figo is the man to listen imo
Sorry for your loss. EPIX is just getting started. Huge moves expected. GlTU
The investment group that shorted this made a miscalculation. Now desperately trying to get longs to sell. Short trap established. Watch for the gapper tomorrow.
Yes it was. Like dogs w/o bones;)
I agree. Pure speculation, but this is what runs 90% of penny stocks. This one was severely bashed more than others Ive see.
Got an Alert on this stock via flipperkeepers on twitter , It said something about $20million given to Karyopharm for one of Epix line of products .. Bought in at .007 and made a nice profit .. This guys r good .. Got alerts on IDOI, LFBG, USOG , SAEIE before they made any run .
Well I think alot of people are a bit miffed the way this was presented and they have every right to be. Not the first time for some of thos associated with today's activity. From what I can find there is some basis for speculation in the fact that EPIX licensed the tech Karyopharm is based on to their founder before they declared bankruptcy. Now IMO, that shows some foresight and makes Karyopharm beholding to EPIX in some way.
Exactly right bud. Like they woul say, " yes we are merging", lmao. Some folks go to all lengths to beat one down, lol.
Like she would acknowledge it to someone emailing that question, lol. What did you think she would say. Yes we are doing a merger, but shhhhhh, don't tell anyone until you see the filing, lmao. I don't know if there is a merger or not, but that post is funny.
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1332
|
Created
|
08/31/07
|
Type
|
Free
|
Moderators |
EPIX Pharmaceuticals, Inc.,
a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery platform. The company's therapeutic product candidates in development include PRX-08066 that completed Phase IIa clinical trial for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease; PRX-03140, which is in Phase IIa clinical trial for the treatment of Alzheimer's disease; PRX-00023, which is in Phase IIb clinical trial for the treatment of depressive disorder; and PRX-07034, which is in Phase Ib clinical trial for the treatment of obesity and cognitive impairment associated with schizophrenia. Its imaging agents comprise Vasovist, an injectable intravascular contrast agent that provides enhanced imaging of the vascular system using magnetic resonance angiography; and EP-2104R that enables the identification of blood clots using MRI. EPIX Pharmaceuticals has collaborations with SmithKline Beecham Corporation; Amgen, Inc.; Cystic Fibrosis Foundation Therapeutics Incorporated; and Bayer Schering Pharma AG, Germany. The company was founded in 1988 as Metacorp, Inc. and changed its name to METASYN, Inc. in May 1989. It further changed its name to EPIX Medical, Inc. in May 1996 and then to EPIX Pharmaceuticals Inc. in September 2004. EPIX Pharmaceuticals Inc. is headquartered in Lexington, Massachusetts.
Homepage EPIX Pharmaceuticals: http://www.epixpharma.com/ - (781) 761-7600
Yahoo Key Statistics: http://finance.yahoo.com/q/ks?s=EPIX.OB - Enterprise Value August 19, 2009: $86.49M
)
Factsheet Epix December 2007
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=epix
Company Information
Recent News
The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept((R))(10 mg). Based on the marked progress during the original two week study, the patient's daughter sought continued compassionate use of PRX-03140 for her mother and a protocol was submitted to the FDA and approved. The progress seen in the first 2-week study has continued during the past two years (19 months of dosing) and four FDA approved 6-month open label extensions. The latest open label extension will be administered under a new Physician-Sponsored IND under the supervision of Dr. Lucy Hornstein(1). "When I was approached by the patient's daughter to continue the compassionate use therapy of PRX-03140 for her mother, I was compelled by the progress her mother had experienced and the overall apparent safety of the drug," notes Dr. Hornstein.
On July 20, 2009, EPIX Pharmaceuticals, Inc. (the "Company") entered into an Assignment for the Benefit of Creditors (the "Assignment") in accordance with Massachusetts law. The purpose of the Assignment is to conclude the Company's operations and provide for an orderly liquidation of its assets. The Assignment is a common law business liquidation mechanism under Massachusetts law that is an alternative to a formal bankruptcy proceeding. Under the terms of the Assignment, the Company transferred all of its assets to an assignee for orderly liquidation and distribution of the proceeds to the Company's creditors. The designated assignee for the Company is Joseph F. Finn, Jr. at Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481.
The PRX-03140 program will be sold at auction on Wednesday, October 21 at 3 pm EDT. Please contact Joseph F. Finn, Jr. at 781-237-8840 if you are interested in participating in the auction.
SOURCE Joseph F. Finn, Jr., C.P.A.
EPIX PHARMACEUTICALS ANNOUNCES THE P2Y2 GASTROINTESTINAL PROGRAM
Sep 01, 2009 (AsiaPulse via COMTEX) -- MEDIA RELEASE PR35934
(Full text of statement. Contact details below.)
EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
WELLESLEY HILLS, Mass., Sept. 2 /PRNewswire-AsiaNet/ --
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that the P2Y2 Gastrointestinal Early Development Candidate Program will be part of the intellectual property offered for sale at the September 30, 2009 auction.
The P2Y2, an Early Development Candidate Program, is a small molecule, oral, non-absorbed agonist for treatment of constipation.
The intellectual property, regulatory dossier and clinical inventory will be sold at auction on September 30, 2009.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement ("CDA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation.
He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net
SOURCE:: Joseph F. Finn, Jr., C.P.A.
Share Structure and Company Information
EPIX Pharmaceuticals, Inc. 4 Maguire Road Lexington, MA 02421
|
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |